A better way to treat ACE inhibitor angioedema in the ED

May 14, 2014

Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.

In angioedema, experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.

But that therapy doesn't always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.

"ACE inhibitors are a common treatment in patients with and hypertension," says Joseph Moellman, MD, associate professor of . "It is also the most common etiology of patients presenting to the with angioedema."

Moellman says there's currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.

In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.

They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.

After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.

Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results. He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.

Explore further: Study targets treatment for serious ACE inhibitor side effect

Related Stories

rhC1INH cuts attack frequency in hereditary angioedema

November 9, 2012

(HealthDay)—For patients with hereditary angioedema (HAE), weekly administration of recombinant C1INH (rhC1INH) is well tolerated and is associated with a reduction in attack frequency, according to a study published online ...

Recommended for you

Scientists use 'virtual heart' to model heart failure

June 23, 2016

A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death. This "virtual heart" could help medical researchers study new drug therapies ...

Blacks with AFib at greater risk for adverse outcomes

June 22, 2016

Blacks with atrial fibrillation (AFib) have nearly double the risk than their white counterparts of stroke, heart failure, coronary heart disease (CHD) and mortality from all causes, according to a study published today in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.